Abstract
Angiogenesis, the formation of new blood vessels is essential for diverse physiological processes such as development, but also for pathological conditions like tumor growth. Most studied in this context are tyrosine kinase signaling pathways such as those involving vascular endothelial growth factor (VEGF). There is however accumulating evidence that more pathways are as essential for angiogenesis. Knockout studies of factors in transforming growth factor β (TGF-β) signaling have for example showed that also this pathway is indispensable for angiogenesis. This review highlights our understanding of TGF-β signaling in vascular development and angiogenesis. In particular, we focus on recent insights into the role of the TGF-β type I receptor ALK1 and co-receptor endoglin in tumor angiogenesis, which provide opportunities for the development of new anti-angiogenesis therapies for treatment of cancer patients.
Keywords: ALK1, angiogenesis, BMP, cancer, Endoglin, Smad, TGF-β, anti-angiogenesis therapy, vascular development, pathological conditions, blood pressure and vascular tone, endothelial cells, tumor growth., tumorigenesis, kinase-domains
Current Pharmaceutical Biotechnology
Title: TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Volume: 12 Issue: 12
Author(s): Laurens A. van Meeteren, Marie-Jose Goumans and Peter ten Dijke
Affiliation:
Keywords: ALK1, angiogenesis, BMP, cancer, Endoglin, Smad, TGF-β, anti-angiogenesis therapy, vascular development, pathological conditions, blood pressure and vascular tone, endothelial cells, tumor growth., tumorigenesis, kinase-domains
Abstract: Angiogenesis, the formation of new blood vessels is essential for diverse physiological processes such as development, but also for pathological conditions like tumor growth. Most studied in this context are tyrosine kinase signaling pathways such as those involving vascular endothelial growth factor (VEGF). There is however accumulating evidence that more pathways are as essential for angiogenesis. Knockout studies of factors in transforming growth factor β (TGF-β) signaling have for example showed that also this pathway is indispensable for angiogenesis. This review highlights our understanding of TGF-β signaling in vascular development and angiogenesis. In particular, we focus on recent insights into the role of the TGF-β type I receptor ALK1 and co-receptor endoglin in tumor angiogenesis, which provide opportunities for the development of new anti-angiogenesis therapies for treatment of cancer patients.
Export Options
About this article
Cite this article as:
A. van Meeteren Laurens, Goumans Marie-Jose and ten Dijke Peter, TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy, Current Pharmaceutical Biotechnology 2011; 12 (12) . https://dx.doi.org/10.2174/138920111798808338
DOI https://dx.doi.org/10.2174/138920111798808338 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry An Enriched Population of CD45, CD34 and CD117 Stem Cells in Human Umbilical Cord Blood for Potential Therapeutic Regenerative Strategies
Current Neurovascular Research Multiparametric MRI Evaluation of Developmental Venous Anomalies in the Brain: Association with Signal Changes on FLAIR in Patients with Multiple Sclerosis
Current Medical Imaging Single-cell RNA Sequencing: In-depth Decoding of Heart Biology and Cardiovascular Diseases
Current Genomics Advances in Sickle Cell Disease Treatment: from Drug Discovery Until the Patient Monitoring
Cardiovascular & Hematological Agents in Medicinal Chemistry Human Amniotic Membrane: Clinical Uses, Patents And Marketed Products
Recent Patents on Regenerative Medicine Genetic Basis, Nutritional Challenges and Adaptive Responses in the Prenatal Origin of Obesity and Type-2 Diabetes
Current Diabetes Reviews The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery The Extracellular Bacterial HtrA Proteins as Potential Therapeutic Targets and Vaccine Candidates
Current Medicinal Chemistry Editorial (Thematic Issue: Pharmacologic Strategies with Afterload Reduction in Low Cardiac Output Syndrome After Pediatric Cardiac Surgery)
Current Vascular Pharmacology Arterial Dilatation-Related Diseases: The Prerequisite Condition of Arterial Elastic Tissue Damage and Endovascular Treatment
Recent Patents on Medical Imaging Editorial [Hot Topic: New Avenues of Research on Multiple Sclerosis from the Perspective of Chronic Cerebrospinal Venous Insufficiency Paradigm (Guest Editor: Marian Simka)]
Reviews on Recent Clinical Trials MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Antimalarial Drugs in Pregnancy: A Review
Current Drug Safety The Fetal Origins of Obesity: Early Origins of Altered Food Intake
Endocrine, Metabolic & Immune Disorders - Drug Targets Vital Elements of the Wnt-Frizzled Signaling Pathway in the Nervous System
Current Neurovascular Research Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Current Pharmaceutical Design Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology